Editor's Pick: Advances and Perspectives in Urinary Bladder Cancer Nanotherapy

European Medical Journal Urology

Nelson Durán¹  Amedea B. Seabra²  Wagner J. Fávaro³  Rogério C. da Silva³  Joel G. de Souza³ 

[1] Center for Natural and Human Sciences, Universidade Federal do ABC, São Paulo, Brazil. Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), São Paulo, Brazil. NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, Brazil.Institute of Chemistry, BiolChemLab., Universidade Estadual de Campinas, Campinas, Brazil ;Center for Natural and Human Sciences, Universidade Federal do ABC, São Paulo, Brazil. Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), São Paulo, Brazil. NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, Brazil;Laboratory of Urogenital Carcinogenesis and Immunotherapy, Department of Structural and Functional Biology, Universidade Estadual de Campinas, Campinas, Brazil;

关键词: Bladder cancer;    drug delivery;    immunotherapy;    nanobiotechnology;    nanomedicine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Bladder cancer treatment remains a challenge in the pharmaceutical field due to the recurrence and progression of the disease, as well as the pronounced side effects associated with the available therapeutic modalities. Although important strategies have been investigated in different clinical trial phases, efficient and well-tolerated treatment approaches need to be developed to improve therapeutic efficacy and the quality of life for bladder cancer patients. This review discusses conventional protocols used in the clinical setting, detailing the use of Bacillus Calmette–Guérin, new immunomodulators, and drug delivery systems. New therapeutic approaches have been investigated with the aim of better therapeutic efficacy with low rates of recurrence and progression of non-muscle invasive bladder cancer and muscle invasive bladder cancer. Therefore, this review highlights the progression of therapy with the use of conventional treatments and the recent progress achieved from the use of innovative strategies, such as nanoparticles for sustained, controlled drug delivery and increased drug uptake by tumour cells.

【 授权许可】

Unknown